Homepage Top Section2

The treatment is intended for usage in adults with priorly untreated la/mUC. This development marks a significant step towards potentially offering an alternative to the current standard platinum-containing

The facility is designed to bolster in-house production of drug substances for Investigational New Drug (IND)-enabling studies and trials. This development is pivotal for the company’s proprietary and

UGN-102 for intravesical solution is a new drug formulation of mitomycin. The drug utilises UroGen’s proprietary RTGel technology, which allows for sustained release and prolonged exposure to bladder

The OpCT-001 iPSC cell therapy candidate is intended for treating primary photoreceptor diseases. The latest move marks the first iPSC therapy candidate to be licensed from the strategic

This collaboration aims to improve the evaluation process for CAR T therapy for cancer patients. It focuses on five crucial factors to ensure timely and personalised care for

The approval from the Ministry of Health, Labor and Welfare (MHLW) marks a significant milestone in the treatment of the ultra-rare, fatal paediatric disease characterised by accelerated aging.

Financial terms of the deal were undisclosed. The move is set to enhance Kindeva’s drug-delivery capabilities by adding a new platform to its portfolio. Kindeva CEO Milton Boyer

Located in Mississauga, Canada, the 3,300ft2 facility is designed for the development and scaling of monoclonal antibodies and other mammalian-based therapeutic proteins. The facility will provide a comprehensive

This label update is based on findings from the Phase III LIBERTY-AD-HAFT trial, the first to evaluate a biologic for this patient group. Dupixent, a fully human monoclonal